SCHEDULE: Venrock Entities Report 9.9% Stake in VOR Biopharma

Several Venrock-affiliated entities have collectively reported beneficial ownership of 9.9% of VOR Biopharma's common stock as of June 30, 2026, due to a beneficial ownership blocker.

Summary

• Multiple Venrock entities, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, and Venrock Healthcare Capital Partners EG, L.P., have filed a Schedule 13G/A.
• As of June 30, 2026, these entities collectively beneficially own 5,676,370 shares of VOR Biopharma's common stock.
• This ownership represents 9.9% of the outstanding common stock, based on 54,185,877 shares outstanding as of May 7, 2026, plus shares issuable from pre-funded warrants.
• The ownership stake is capped by a 'Beneficial Ownership Blocker' provision in the pre-funded warrants, preventing exercise beyond 9.99% ownership.
• Nimish Shah and Bong Koh are identified as key individuals associated with the management entities and hold power of attorney.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but capped ownership stake. The presence of a beneficial ownership blocker indicates a strategic, rather than controlling, investment approach.

Positives

• Significant ownership stake of 9.9% indicates substantial investor confidence in VOR Biopharma.
• The filing clearly defines the reporting persons and their respective ownership structures.
• The beneficial ownership blocker, while limiting, suggests a structured and controlled investment approach.

Negatives

• The beneficial ownership blocker limits the ability to increase the stake beyond 9.99%, potentially capping upside for the investors.
• The filing does not provide specific details on the investment strategy or the rationale behind the capped ownership.

Risks

• The 'Beneficial Ownership Blocker' in the pre-funded warrants restricts the exercise of these warrants, capping the aggregate beneficial ownership at 9.99% to avoid triggering a change of control or other adverse consequences.
• The reliance on pre-funded warrants and their associated blockers suggests a potentially complex financial structure for the investment.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a disclosure of current beneficial ownership as of a specific date.

Management Comments

• The Reporting Persons certify that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than in connection with a nomination under Rule 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies, particularly in the biopharmaceutical sector where investments can be long-term and strategic. The presence of a beneficial ownership blocker is a mechanism to manage ownership levels and avoid regulatory scrutiny or triggering change-of-control provisions.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant ownership block, which may influence market perception and trading activity.
• Management: The 9.9% stake, capped by a blocker, suggests the investors are not seeking immediate control but are significant stakeholders whose actions could be influential.
• Creditors: No direct impact is indicated, as the filing pertains to equity ownership.

Next Steps

• The Reporting Persons will continue to monitor their investment in VOR Biopharma.
• Future actions will be guided by the terms of the pre-funded warrants and the beneficial ownership blocker.

Key Dates

Keywords

VOR Biopharma, Schedule 13G, Venrock Healthcare Capital Partners, Beneficial Ownership, Pre-funded Warrants, Investment Stake, Ownership Cap